Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 1-month safety study for bilateral and higher (0.64 mg) dosing of OTO-313 in Tinnitus

Next Previous
X
Search
Trial Profile

A 1-month safety study for bilateral and higher (0.64 mg) dosing of OTO-313 in Tinnitus

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gacyclidine (Primary)
  • Indications Tinnitus
  • Focus Adverse reactions
  • Sponsors Otonomy [CEASED]

    • Most Recent Events

    • 10 Nov 2022 According to an Otonomy media release, the company discontinued development of OTO-313 based on data from NCT04829214 trial.
    • 10 Nov 2022 Status changed from active, no longer recruiting to discontinued, according to a an Otonomy media release.
    • 25 Jul 2022 According to an Otonomy media release, top-line results are expected in the third quarter of 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top